Oral combination chemotherapy of 5'-deoxy-5-fluorouridine (furtulon) and cyclophosphamide for advanced breast cancer.
- Author:
Bing-he XU
1
;
Ying-juan ZHANG
;
Xiao ZHENG
;
Qing WU
;
Xiao-ting WU
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Breast Neoplasms; drug therapy; Cyclophosphamide; administration & dosage; adverse effects; Female; Floxuridine; administration & dosage; adverse effects; Humans; Middle Aged
- From: Chinese Journal of Oncology 2003;25(3):282-284
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of the oral combination chemotherapy of furtulon (FTL) and cyclophosphamide (CTX) for advanced breast cancer (ABC).
METHODSFrom Jun 2000 to Jun 2002, eighty-three patients with ABC were treated with the two oral drugs as combined chemotherapy. The mean number of cycles was 5, median number of cycles was 6 (range 2-6).
RESULTSThe overall response rate was 45.8%, The median time to progression was 6 months. The treatment was well tolerated, with related Grade 3 clinical adverse effect being only nausea and vomiting in 2 patients (2.4%) and mild hematologic toxicities.
CONCLUSIONOral combined chemotherapy of FTL and CTX, being convenient and safe, is effective for patients with advanced breast cancer.
